Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Sarah James reiterates LifeMD (NASDAQ:LFMD) with a Overweight and maintains $15 price target.
Cantor Fitzgerald analyst Sarah James reiterates LifeMD (NASDAQ:LFMD) with a Overweight and maintains $15 price target.
LifeMD (NASDAQ:LFMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.12) by 150...
Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the price target from $12 to $10.
LifeMD, Inc. (NASDAQ:LFMD) today announced the launch of private health insurance acceptance for its virtual primary care servi...
Keybanc analyst Scott Schoenhaus initiates coverage on LifeMD (NASDAQ:LFMD) with a Overweight rating and announces Price Tar...
